## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.9% below STRENGTH zone (4.0-10.0%); PEG 4.06 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (55% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($650.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Precision Trading with Idexx Laboratories Inc. (IDXX) Risk Zones**
- Source: Stock Traders Daily | 20251229T061600 | Somewhat-Bearish | Relevance: 100%
- This article discusses precision trading strategies for Idexx Laboratories Inc. (IDXX) based on AI-generated risk zones. It highlights a weak near and mid-term sentiment but a strong long-term outlook, presenting specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies. The analysis emphasizes an exceptional risk-reward short setup with a 25.9:1 ratio.

**2. Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?**
- Source: Yahoo Finance Singapore | 20251229T150825 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) stock has outperformed its Medical sector peers this year, gaining 66.5% compared to the sector's average of 8.2%. The company, holding a Zacks Rank #2 (Buy), also shows strong analyst sentiment with a 2.5% increase in its full-year earnings estimate over the past 90 days. Artivion (AORT) is another medical stock demonstrating strong performance within the same industry group as IDEXX.

**3. BankPlus Trust Department Purchases 1,830 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251228T080819 | Bullish | Relevance: 95%
- BankPlus Trust Department significantly increased its stake in IDEXX Laboratories, purchasing 1,830 additional shares to bring its total holdings to 1,962 shares, valued at approximately $1.254 million. The company recently exceeded Q3 earnings expectations, reporting an EPS of $3.22 and revenue of $1.11 billion, leading to several analysts raising their price targets and a consensus "Moderate Buy" rating. Despite bullish institutional activity, an EVP recently sold a substantial portion of her shares, reducing her position by over 30%.

**4. Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical**
- Source: Nasdaq | 20251230T110828 | Bullish | Relevance: 94%
- The medical instruments industry is experiencing a transformative shift due to generative AI (genAI) and ongoing M&A trends, despite global economic slowdowns and supply chain issues. Companies like Veracyte, IDEXX Laboratories, and Intuitive Surgical are adapting well to these changes by leveraging innovative technologies and strategic initiatives, leading to an uptrend in their stock prices. The industry's near-term outlook remains challenging due to various economic headwinds, but individual companies with strong earnings potential are positioned for growth.

**5. Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical**
- Source: Yahoo Finance | 20251230T190758 | Bullish | Relevance: 80%
- Zacks Equity Research highlights Veracyte (VCYT), IDEXX Laboratories (IDXX), and Intuitive Surgical (ISRG) as key players in the Medical Instruments industry. Despite macroeconomic headwinds and regulatory adjustments, these companies have adapted well, leveraging generative AI and M&A trends. The industry outlook, however, remains subdued according to the Zacks Industry Rank, even as the global AI in healthcare market projects significant growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.1x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.06 signals overvaluation risk, limited margin of safety. Forward P/E 47.3x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.6B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.06 |
| Forward P/E | 47.3 |
| Current P/E | 52.9 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.4% to -2.9% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.8pp (needs >4.0% for momentum thesis). Underperforming sector by 4.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). MACD histogram bearish (-3.42), momentum weakening. RSI neutral at 41. Volume at 55% of 20MA suggests lack of conviction. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.85% (CS: 15) | Weak |
| RSI_14 | 41.2 | Neutral |
| MACD Histogram | -3.42 | Bearish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 1.176x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $682.32
- **Stop Loss:** $650.88 (4.6% risk)
- **Target:** $713.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $27,975.12
- **Portfolio %:** 27.98%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*